Is Gilead (GILD) One of the Most Undervalued NASDAQ Stocks to Buy Right Now?

Gilead Sciences Inc. (NASDAQ:GILD) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 25, Gilead Sciences announced FDA approval for Trodelvy as a first-line treatment for metastatic triple-negative breast cancer (mTNBC). It is now approved as a single agent or in combination with Keytruda, becoming the first antibody-drug conjugate authorized for this setting regardless of PD-L1 status.

The approval follows successful Phase 3 trials showing significantly improved progression-free survival and more durable responses compared to standard chemotherapy. Based on these results, the National Comprehensive Cancer Network now lists Trodelvy as a category 1 preferred first-line treatment.

This milestone expands Trodelvy’s clinical utility, building on its existing use in later-stage breast cancer treatments. With over 75,000 patients treated globally, this new indication provides a vital standard-of-care option for a disease that has historically lacked diverse first-line therapies.

Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.